Neuland Laboratories Ltd
NEULANDLABNeuland Laboratories Ltd
NEULANDLAB


Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
24.49 | 6.56 | 0.20% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
44.48 | 5.11 | 0.70% |
Forecast & Ratings
Detailed Forecastfrom 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Neuland Laboratories Limited is engaged in manufacturing active pharmaceutical ingredient (API). The Company also provides custom manufacturing solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 469.93 | 511.75 | 580.06 | 531.94 | 670.32 | 766.60 | 953.01 | 953.16 | 1,200.95 | 1,471.15 | ||||||||||
Raw Materials | 266.42 | 259.57 | 272.33 | 283.36 | 363.03 | 394.41 | 443.04 | 441.79 | 491.98 | 1,048.71 | ||||||||||
Power & Fuel Cost | 22.53 | 22.24 | 25.78 | 25.95 | 26.81 | 32.75 | 39.21 | 42.21 | 48.62 | |||||||||||
Employee Cost | 51.81 | 65.38 | 92.74 | 102.99 | 110.46 | 123.56 | 149.74 | 182.47 | 201.79 | |||||||||||
Selling & Administrative Expenses | 41.47 | 51.81 | 39.45 | 47.35 | 46.15 | 46.42 | 73.93 | 63.21 | 80.80 | |||||||||||
Operating & Other expenses | 20.30 | 30.53 | 42.25 | 17.33 | 62.01 | 63.68 | 84.17 | 78.78 | 96.16 | |||||||||||
EBITDA | 67.40 | 82.22 | 107.51 | 54.96 | 61.86 | 105.78 | 162.92 | 144.70 | 281.60 | 422.44 | ||||||||||
Depreciation/Amortization | 15.32 | 15.74 | 19.23 | 22.10 | 25.86 | 31.28 | 39.68 | 49.04 | 52.78 | 54.91 | ||||||||||
PBIT | 52.08 | 66.48 | 88.28 | 32.86 | 36.00 | 74.50 | 123.24 | 95.66 | 228.82 | 367.53 | ||||||||||
Interest & Other Items | 27.36 | 24.48 | 21.09 | 18.93 | 15.66 | 21.57 | 17.90 | 13.50 | 13.07 | 13.67 | ||||||||||
PBT | 24.72 | 42.00 | 67.19 | 13.93 | 20.34 | 52.93 | 105.34 | 82.16 | 215.75 | 353.86 | ||||||||||
Taxes & Other Items | 8.78 | 14.68 | 20.32 | 1.87 | 3.90 | 36.72 | 24.71 | 18.34 | 52.23 | 87.63 | ||||||||||
Net Income | 15.94 | 27.32 | 46.87 | 12.06 | 16.44 | 16.21 | 80.63 | 63.82 | 163.52 | 266.23 | ||||||||||
EPS | 18.52 | 30.40 | 52.25 | 13.47 | 15.04 | 12.60 | 62.85 | 49.74 | 127.45 | 207.51 | ||||||||||
DPS | 1.50 | 2.00 | 0.00 | 0.00 | 0.00 | 2.00 | 5.00 | 5.00 | 10.00 | 10.00 | ||||||||||
Payout ratio | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 | 0.16 | 0.08 | 0.10 | 0.08 | 0.05 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Neuland Laboratories Ltd | 39.87 | 6.56 | 0.20% |
Sun Pharmaceutical Industries Ltd | 35.09 | 5.01 | 0.93% |
Cipla Ltd | 35.23 | 4.16 | 0.69% |
Dr Reddy's Laboratories Ltd | 21.37 | 4.14 | 0.69% |
Price Comparison
Compare NEULANDLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.37%
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Neuland Laboratories Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8296% | Percentage of the fund’s portfolio invested in the stock 0.57% | Change in the portfolio weight of the stock over the last 3 months -0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/125 (-7) |
WhiteOak Capital Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1657% | Percentage of the fund’s portfolio invested in the stock 0.45% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 83/131 (-1) |
WhiteOak Capital Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0861% | Percentage of the fund’s portfolio invested in the stock 0.51% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 80/129 (+5) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 11, 2023
Dividend/Share
₹10.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateJun 29, 2021
Dividend/Share
₹3.00
Ex DateEx Date
Jun 29, 2021
Cash Dividend
Ex DateEx DateNov 10, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Nov 10, 2020
Cash Dividend
Ex DateEx DateFeb 18, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Feb 18, 2020
News & Opinions
MSCI index rejig may result in $1.4b inflows into stocks
3 months ago•Economic Times
Vijay Kedia on why he sold 2 IT stocks; his temptation to sell shares & pharma scrip that tested his patience
6 months ago•Business Today
Garden Reach Shipbuilders & Engineers Ltd leads gainers in ‘A’ group
1 year ago•Business Standard
Hester Biosciences Ltd leads losers in ‘A’ group
1 year ago•Business Standard
Neuland Labs CFO Deepak Gupta resigns
1 year ago•Business Standard
Great Eastern Shipping Company Ltd leads losers in ‘A’ group
1 year ago•Business Standard
Neuland Laboratories consolidated net profit rises 14.20% in the June 2022 quarter
1 year ago•Business Standard
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.69%, vs industry avg of 8.45%
Increasing Market Share
Over the last 5 years, market share increased from 0.26% to 0.38%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 68.44%, vs industry avg of 9.82%